The Clinical Research Management Office (CRMO) shared resource operates from a centralized Lombardi Cancer Center facility which is dedicated to the support of programmatic clinical investigations. Personnel in the CRMO work under the direction of the core's supervisor to support all operational aspects of clinical research protocols, from the inception of a study design to publication of the results. The main functions of the CRMO include: 1) quality assurance and compliance with protocol guidelines; 2) identification of patients for study; 3) education of clinical fellows and nurses in trial design and conduct; 4) accurate and complete data collection; and 5) interfacing with other relevant groups such as the Institutional Review Board, Pharmacy, Georgetown University Hospital Tumor Registry, and the Biostatistics Shared Resource. The CRMO provides centralization, consistency, cost-effectiveness, and quality control for resources and service activities that are critical to the conduct of clinical research. It is the intent of the CRMO to provide a service to peer-review funded programs of the cancer center. Research programs in breast cancer, bone marrow transplantation, AIDS, experimental therapeutics, hematology/lymphoma, radiation oncology, prostate cancer, and the developmental programs of gynecological oncology, neuro-oncology, and psycho-oncology have received support in the conduct of clinical trials from CRMO personnel.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA051008-07
Application #
5207617
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
1996
Total Cost
Indirect Cost
Tassi, Elena; Garman, Khalid A; Schmidt, Marcel O et al. (2018) Fibroblast Growth Factor Binding Protein 3 (FGFBP3) impacts carbohydrate and lipid metabolism. Sci Rep 8:15973
Lipkus, Isaac M; Mays, Darren (2018) Comparing harm beliefs and risk perceptions among young adult waterpipe tobacco smokers and nonsmokers: Implications for cessation and prevention. Addict Behav Rep 7:103-110
Speidell, Andrew P; Demby, Tamar; Lee, Yichien et al. (2018) Development of a Human APOE Knock-in Mouse Model for Study of Cognitive Function After Cancer Chemotherapy. Neurotox Res :
Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620
Coia, Heidi; Ma, Ning; Hou, Yanqi et al. (2018) Prevention of Lipid Peroxidation-derived Cyclic DNA Adduct and Mutation in High-Fat Diet-induced Hepatocarcinogenesis by Theaphenon E. Cancer Prev Res (Phila) 11:665-676
Lee, Yichien; Rodriguez, Olga C; Albanese, Chris et al. (2018) Divergent brain changes in two audiogenic rat strains: A voxel-based morphometry and diffusion tensor imaging comparison of the genetically epilepsy prone rat (GEPR-3) and the Wistar Audiogenic Rat (WAR). Neurobiol Dis 111:80-90
Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723
Ory, Virginie; Kietzman, William B; Boeckelman, Jacob et al. (2018) The PPAR? agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ. Breast Cancer Res Treat 169:47-57
Edwardson, Matthew A; Zhong, Xiaogang; Fiandaca, Massimo S et al. (2018) Plasma microRNA markers of upper limb recovery following human stroke. Sci Rep 8:12558
Smith, Jill P; Wang, Shangzi; Nadella, Sandeep et al. (2018) Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. Cancer Immunol Immunother 67:195-207

Showing the most recent 10 out of 1120 publications